UPDATE: Helus Pharma (HELP) - The Pooled Data Trick and the $5.25 Reality Check

Decoding the Helus Pharma Sell-Off: Weak Remission Margins and the Dilution Gap Realized.

Mar 07, 2026

∙ Paid

Context: The moment of truth for Helus Pharma’s Q1 2026 clinical catalyst has arrived. On Thursday, March 5, the company released topline Phase 2 data for HLP004 (deuterated DMT) in Generalized Anxiety Disorder (GAD). The market reaction was a violent round-trip: the stock crept up to $8.52 on Wednesday in anticipation of the readout, and then cratered to close at $5.25 at close on Friday.

I’ve been tracking the Dilution Gap and the risk of functional unblinding for months. The new press release provides a masterclass in how biopharma companies try to massage mediocre clinical results — and why you must always read past the headlines.

Continue reading this post for free, courtesy of Biotech Distilled.

Or purchase a paid subscription.